Fate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.58), $0.28 better than the analyst estimate of ($0.86). Revenue for the quarter came in at $44.34 million versus the consensus estimate of $17.88 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.